Fri, Nov 8, 9:14 PM (253 days ago)
Entera Bio Ltd. (ENTX) reported significant financial challenges in its Q3 2024 results, with a net loss of $3.0 million for the quarter and $7.2 million for the nine-month period, reflecting a 27% increase in quarterly losses year-over-year. Revenues reached $42,000 for Q3 and $99,000 year-to-date, primarily from a research services agreement, indicating minimal income generation as the company focuses on developing its oral peptide therapies, including EB613 and EB612. Research and development expenses totaled $1.5 million for Q3 2024, slightly up from $1.4 million in Q3 2023, while general and administrative expenses surged by 50% to $1.5 million, highlighting rising operational costs. The company ended the quarter with $6.9 million in cash and cash equivalents, which management believes will sustain operations into Q3 2025. However, uncertainties surrounding regulatory approvals and funding needs for future studies raise substantial doubt about its ability to continue as a going concern. The ongoing geopolitical instability in Israel has not yet materially affected Entera's operations, but the situation remains fluid and could impact future business prospects.